论文部分内容阅读
目的 观察普米克气雾剂治疗儿童哮喘前后的最高呼气峰流速值 (PEF)及血清嗜酸细胞阳离子蛋白 (ECP)的变化。方法 对 113例儿童哮喘病人 ,使用普米克气雾剂 [(2 0 0～ 80 0 ) μg/d],3月～ 1年。采用峰流速仪监测PEF ,并用荧光免疫法 ,使用PharmaciaCAP系统 (瑞典 )测定部分病儿治疗前后的血清ECP。结果 使用普米克治疗后 ,PEF明显增高 ,3个月、6个月、1年的PEF占预计值的百分比 (PEF % )分别为 (93.6± 5 .4) ,(93.0± 4.2 ) ,(94.5± 4.5 ) ,与治疗前 (70 .4± 19.1)比较 ,差异有显著性 ,P <0 .0 1。治疗后ECP为 (7.5± 2 .7)μg/L ,比治疗前 (2 4.0± 17.1) μg/L明显下降 ,P <0 .0 1,差异有显著性。结论 普米克气雾剂治疗儿童哮喘副作用小、安全有效、方法简便 ,用于儿童哮喘的中、长期防治 ,值得推广。
Objective To investigate the changes of peak expiratory flow velocity (PEF) and serum eosinophil cationic protein (ECP) before and after treatment of Pulmicort aerosol in children with asthma. Methods Thirty-one children with asthma were treated with Pulmicort aerosol [(200 ~ 80 0) μg / d] for 3 months to 1 year. PEF was monitored using a peak flow meter and serum ECP was measured before and after treatment in some of the sick children using the PharmaciaCAP system (Sweden) using fluorescence immunoassay. Results The PEF was significantly increased after treatment with Pulmicort, PEF% of 3 months, 6 months and 1 year were (93.6 ± 5. 4), (93.0 ± 4.2) and (94.5 ± 4.5), compared with before treatment (70.4 ± 19.1), the difference was significant, P <0. The ECP after treatment was (7.5 ± 2 .7) μg / L, which was significantly lower than that before treatment (2 4.0 ± 17.1) μg / L, P <0.01, the difference was significant. Conclusion Pulmicort aerosol treatment of children with asthma side effects, safe and effective, the method is simple, for children with asthma in the long-term prevention and treatment, it is worth promoting.